Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium y 90 monoclonal antibody bre-3
- Development stage
- Phase 1
- Lead developer
- Cancer Research Institute of Contra Costa
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Yttrium y 90 monoclonal antibody bre-3 is a radioimmunotherapeutic agent composed of the BrE-3 monoclonal antibody conjugated to the radioisotope yttrium-90. The BrE-3 is an IgG1 (murine or humanized) monoclonal antibody that targets an epitope of epithelial glycoprotein mucin (milk mucin), a protein frequently expressed in human breast cancer cells. By binding to this tumor-associated antigen and delivering cytotoxic beta radiation from the attached yttrium‑90 isotope, it aims to selectively destroy cancer cells while sparing normal tissue. It has been studied primarily for metastatic breast cancer in early-phase clinical trials[1][4][5][6][8].
- Other names
- yttrium Y 90 monoclonal antibody BrE-3Yttrium-90-labeled huBrE-3 monoclonal antibodyYttrium90-labeled huBrE-3 monoclonal antibodyYttrium 90-labeled huBrE-3 monoclonal antibody
02
Targets
MUC6
Beyond the preview
Go deeper on yttrium y 90 monoclonal antibody bre-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium y 90 monoclonal antibody bre-3.